Results 61 to 70 of about 1,266 (177)

Drugs Used in the Treatment of Viral Infections for the Prevention of Airway Remodeling in Asthma

Mediators of Inflammation, Volume 2025, Issue 1, 2025.
One of the main causes of the exacerbation of chronic airway inflammatory diseases is respiratory virus infections. The most prevalent viruses that can infect humans multiple times a year are rhinovirus (RV) and respiratory syncytial virus (RSV). Because remodeling factors like matrix metalloproteinases (MMPs), which are released by infiltrating ...
Joanna Wieczfinska, Rafal Pawliczak, Mirella Giovarelli   +2 more
wiley   +1 more source

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat fixed-dose combination for chronic obstructive pulmonary disease patients in Italy

Therapeutic Advances in Respiratory Disease, 2016
Background: The objective of this study was to compare the cost-effectiveness of the fixed-dose combination (FDC) of tiotropium + olodaterol Respimat ® FDC with tiotropium alone for patients with chronic obstructive pulmonary disease (COPD) in the ...
Carl Selya-Hammer, Nuria Gonzalez-Rojas Guix, Michael Baldwin, Andrew Ternouth, Marc Miravitlles, Maureen Rutten-van Mölken, Lucas M.A. Goosens, Nasuh Buyukkaramikli, Valentina Acciai   +8 more
doaj   +1 more source

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – Focus on olodaterol

, 2015
Olodaterol (BI 1744 CL) is a novel, once-daily long-acting β2-agonist (LABA) designed with the aim of improving β2-adrenoreceptor selectivity and intrinsic activity. Phase III pivotal trials have documented that olodaterol Respimat Soft Mist inhaler 5 μg
Cazzola, Mario, MATERA, Maria Gabriella, Ora, Josuel   +2 more
core   +1 more source

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease [PDF]

, 2015
Background: This study investigated the effects on 24-h lung function and lung volume of a once-daily fixed-dose combination (FDC) of the long-acting muscarinic antagonist tiotropium and the long-acting beta(2)-agonist olodaterol in patients with chronic
Hébert, Jacques, Grönke, Lars, Beeh, Kai-Michael, Hamilton, Alan, Tetzlaff, Kay, Westerman, Jan, Kirsten, Anne-Marie, Derom, Eric, Derom, EricGE35UZGent8010005136520000-0003-1110-4940F4143B54-F0ED-11E1-A9DE-61C894A0A6B4   +8 more
core   +1 more source

Errors associated with co‐names of medicines: The nomenclature of combination medicinal products

British Journal of Clinical Pharmacology, Volume 90, Issue 11, Page 2705-2712, November 2024.
In comparison to the efforts required to bring a new drug or formulation to the clinic, bestowing a name on a medicine is relatively simple. However, if the name we choose causes confusion—by making its contents ambiguous or if it is too alike another drug—it can precipitate clinical errors.
Oisín N. Kavanagh, Robert Lowe, Jeffrey K. Aronson   +2 more
wiley   +1 more source

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD

Фармакоэкономика, 2017
The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide).
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov   +5 more
doaj   +1 more source

Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials [PDF]

, 2020
Introduction Previous studies demonstrated that tiotropium/olodaterol reduced rates of exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, this should be examined in a wider population.
de la Hoz, Alberto, Xue, Wenqiong, Calverley, Peter MA, Vogelmeier, Claus F, Buhl, Roland, Anzueto, Antonio, Wedzicha, Jadwiga A, Singh, Dave   +7 more
core   +1 more source

A severe tremor caused by a beta2 agonist in a patient with asthma‐chronic obstructive pulmonary disease overlap

Clinical Case Reports, Volume 12, Issue 8, August 2024.
Key Clinical Message A 46‐year‐old male developed respiratory distress due to asthma‐chronic obstructive pulmonary disease overlap and experienced severe tremor caused by beta2 agonist inhalant. We present our successful experience with tizanidine administration.
Kota Nakajima, Kenji Momo
wiley   +1 more source

Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigs. [PDF]

PLoS ONE, 2015
Excessive coughing is a common feature of airway diseases. Different G-protein coupled receptors, including β2-adrenergic receptors (β2-AR), have been implicated in the molecular mechanisms underlying the cough reflex.
Eva Wex, Thierry Bouyssou
doaj   +1 more source

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis [PDF]

Respiratory Research, 2017
Long-acting bronchodilators are the cornerstone of pharmacologic treatment of COPD. The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) and long acting beta-agonists (LABA) olodaterol (OLO) has been introduced as fist line therapy for COPD. This article analyses the evidence of efficacy and safety of the TIO/OLO combination.
Marc Miravitlles, Gerard Urrutia, Alexander G. Mathioudakis, Julio Ancochea   +3 more
openaire   +4 more sources